A new antibody treatment very effectively targets stomach cancer. Termed IMAB362, it is ideal for those who have gastric tumors.
Ganymed Pharmaceuticals is a company that is famous for its immunotherapy treatments against cancer. It recently announced its clinical study concerning IMAB362 which is the first line of treatment against gastric cancer.
Don't Miss: See the first leaked Black Friday 2016 Ad
The matter was raised at the annual meeting. IMAB362 is a monoclonal antibody. It makes a beeline for the cell surface molecule named Claudin18.2. This Phase II Study was carried out on gastric cancer patients. The antibody increased immunity against stomach cancer when it was added as an adjunct to chemotherapy.
Those patients who had higher levels of Claudin18.2 had greater chances of survival. While IMAB362 was tolerated by many of the patients, some of them showed symptoms such as vomiting, nausea and neutropenia.
The majority of patients with stomach cancer have a short span of time to live after their diagnosis. It is a cruel disease. The therapy options are limited too.
Yet these new trials held with IMAB362 hold promise for the future. The highly focused targetting of Claudin18.2 shows scope for the times to come. Stomach cancer may go the way of malaria or small pox in the years that lie ahead.
Compared to those who had IMAB362 antibody treatment done on them, those who underwent chemotherapy alone did not survive in such great numbers.
The survival rate of the former was almost double that of the latter, according to HealthDay. Thus this antibody treatment has healthy salubriety in its very structural-functional makeup.
Finally, those with gastric cancer can live longer and breath free instead of spending their last days dreading death due to their terminal illness. The study involved 161 patients.
Since the current standard treatments leave a lot of room for improvement, scientists are looking forward to IMAB362 as the ideal method of attacking stomach cancer.
Oncologists know that cancer cells can be coaxed into lysis so that the danger to the patient’s life is minimized if not altogether warded off.
Yet the problem lies with the hydra-headed process known as metastasis and the relapses which allow the cancer tumors to regrow from their otherwise dormant state after treatment.
Don't Miss: The Best HDR TVs
To utilize the body’s resources against the tumors in the body is the latest cutting-edge method of fighting cancer. It might even become the norm in the near future.